Oxford Cancer Analytics
Latest round
- Series A
Last raised
- Nov 2024
Total raised
- $16M
Investors
- 13
About Oxford Cancer Analytics
Based in Oxford, UK, and founded in 2020 by co-founders Dr. Peter Jianrui Liu (CEO) and Dr. Andreas Halner (COO), Oxford Cancer Analytics Ltd. operates as a developer of blood-based diagnostic tests for healthcare providers, focusing on early cancer detection using advanced proteomics and artificial intelligence. In January 2025, Oxford Cancer Analytics Ltd. Oxford Cancer Analytics specializes in the development of advanced blood tests intended for early cancer detection, leveraging improved proteomics and artificial intelligence. Their core product offerings include a new generation of blood-based liquid biopsy tests intended to identify cancer biomarkers, specifically proteins indicative of lung cancer. These products are intended for use in clinical settings, targeting healthcare providers and institutions involved in cancer diagnostics and patient care. The geographical market for these products primarily includes North America and Europe, focusing on institutions involved in oncological research and treatment. The revenue model for OXcan is primarily based on partnerships with healthcare institutions and diagnostic laboratories that utilize their liquid biopsy tests. Transactions may occur through direct agreements with hospitals and clinics, where OXcan's products are integrated into their diagnostic services. The company’s revenue structure involves both direct sales to healthcare providers and collaborations with research institutions that require access to their advanced cancer detection technologies. OXcan’s flagship products, based on their proprietary DEcancer platform, are expected to be utilized in a variety of clinical applications, establishing a recurring revenue stream as these institutions adopt the technology for routine cancer screenings and diagnostics. OXcan has targeted entry into the North American and European markets, with strategies in place to establish partnerships in these regions by the end of 2025.
Who invested in Oxford Cancer Analytics
13 investors across 3 rounds
See all investors in Oxford Cancer Analytics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Oxford Cancer Analytics
Who invested in Oxford Cancer Analytics?
Oxford Cancer Analytics has 13 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Oxford Cancer Analytics raised?
Oxford Cancer Analytics has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Oxford Cancer Analytics last raise money?
Oxford Cancer Analytics's most recent round on record is a Series A, in Nov 2024.
What does Oxford Cancer Analytics do?
Based in Oxford, UK, and founded in 2020 by co-founders Dr.
Where is Oxford Cancer Analytics headquartered?
Oxford Cancer Analytics is headquartered in Oxford, UK.
Which VCs invest in companies like Oxford Cancer Analytics?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at Oxford Cancer Analytics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Oxford Cancer Analytics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.